Login to Your Account


Myos, Cloud collaborate to 'muscle in' on new therapeutic category

By Marie Powers
Staff Writer

Friday, July 18, 2014
Myos Corp., which is taking a bifurcated approach in developing products to improve muscle mass, increase mobility and reduce frailty, is going to the "cloud" through a research and development agreement with newco Cloud Pharmaceuticals Inc. Although terms were not disclosed, the partners will focus on identifying and advancing candidates that inhibit targets in the myostatin regulatory pathway and inflammatory mediators associated with sarcopenia and cachexia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription